We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord

Ticker
PMCB

Price
1.23
Stock movement up
+0.01 (0.60%)
Company name
PharmaCyte Biotech Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
14.12M
Ent value
-24.63M
Price/Sales
-
Price/Book
0.29
Div yield
-
Div growth
-
Growth years
-
FCF payout
-214748.36%
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
99.55%
1 year return
-24.77%
3 year return
-12.70%
5 year return
-48.91%
10 year return
-39.96%
Last updated: 2024-12-13

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

DIVIDENDS

PMCB does not pay dividends or no data was received

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.29
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count8.45M
EPS (TTM)3.42
FCF per share (TTM)-0.36

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-5.71M
Net income (TTM)26.94M
EPS (TTM)3.42
EPS (1y forward)-

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash32.64M
Net receivables0.00
Total current assets32.88M
Goodwill0.00
Intangible assets1.55M
Property, plant and equipment0.00
Total assets70.19M
Accounts payable553.95K
Short/Current long term debt0.00
Total current liabilities7.47M
Total liabilities17.15M
Shareholder's equity53.04M
Net tangible assets0.00

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-2.87M
Capital expenditures (TTM)3.00
Free cash flow (TTM)-2.87M
Dividends paid (TTM)22457.23B

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity50.79%
Return on Assets38.38%
Return on Invested Capital50.79%
Cash Return on Invested Capital-5.41%

iO Charts is a Seeking Alpha partner

iO Charts is a Seeking Alpha partner

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.74
Daily high1.80
Daily low1.62
Daily Volume36K
All-time high1080.00
1y analyst estimate-
Beta-0.20
EPS (TTM)3.42
Dividend per share-
Ex-div date-
Next earnings date-

Downside potential

Loading...
Downside potential data
PMCBS&P500
Current price drop from All-time high-99.89%-12.89%
Highest price drop-99.86%-56.47%
Date of highest drop3 Sep 20249 Mar 2009
Avg drop from high-83.44%-11.07%
Avg time to new high381 days12 days
Max time to new high5175 days1805 days

iO Charts is a Seeking Alpha partner

COMPANY DETAILS
PMCB (PharmaCyte Biotech Inc) company logo
Marketcap
14.12M
Marketcap category
Small-cap
Description
PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Employees
2
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...

iO Charts is a Seeking Alpha partner

UNDERSTAND THE BUSINESS
Loading...